Skip to main content

Advertisement

SpringerLink
Log in

Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Aberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC). However, the expression pattern and clinical significance of circulating miR-148/152 family in HCC remain elusive. In this study, we conducted quantitative real-time polymerase chain reaction (qRT-PCR) to examine the levels of serum miR-148a, miR-148b, and miR-152 in 76 HCC cases, as well as 62 controls with benign liver diseases and 55 healthy volunteers. Our results showed that serum levels of three microRNAs (miRNAs) were significantly decreased in HCC cases than those in benign and healthy controls (all P < 0.05). Moreover, they showed strong correlations with each other in HCC group (r = 0.6716, 0.5381, and 0.7712; all P < 0.001). Receiver operating characteristic (ROC) analysis revealed that the combination of circulating miR-148/152 family had an increased area under the curve (AUC) = 0.940 (95 % confidence interval (CI), 0.886–0.973) with the sensitivity of 96.1 % and the specificity of 91.9 %, which were significantly higher than those of serum alpha-fetoprotein (AFP) and three miRNAs alone in differentiating HCC from benign liver diseases. In addition, serum miR-148a and miR-148b were significantly associated with tumor size (P = 0.011 and 0.037) and tumor–node–metastasis (TNM) stage (P < 0.001 and P = 0.034), yet serum miR-152 was only correlated with TNM stage (P = 0.009). Also, dynamic monitoring three miRNAs can help us predict recurrence or metastasis in HCC cases after surgical resection. Besides, Kaplan–Meier analyses demonstrated that the decreased serum miR-148a (P < 0.001) and miR-152 (P = 0.012) was closely correlated with shorten overall survival of HCC patients. Additionally, Cox regression model further indicated that serum miR-148a was strongly associated with the prognosis of HCC patients. Our study suggests that downregulated circulating miR-148/152 family can provide positive diagnostic value for HCC. Moreover, serum miR-148a might be as independent prognostic factor for HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61(1):191–9.

    Article  PubMed  Google Scholar 

  3. Bodzin AS, Busuttil RW. Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7(9):1157–67.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev. 2015;81:62–74.

    Article  CAS  PubMed  Google Scholar 

  5. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo- Miranda A. miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther. 2014;15(11):1444–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015;2015:125094.

    PubMed  PubMed Central  Google Scholar 

  7. Jiang L, Cheng Q, Zhang BH, Zhang MZ. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China. Medicine (Baltimore). 2015;94(10):e603.

    Article  CAS  Google Scholar 

  8. Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med. 2015;9(2):131–51.

    Article  CAS  PubMed  Google Scholar 

  9. Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted players. Mol Cancer. 2013;12:43.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhai R, Kan X, Wang B, Du H, Long Y, Wu H, et al. miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151. Tumour Biol. 2014;35(11):11367–73.

    Article  CAS  PubMed  Google Scholar 

  11. Joshi P, Jeon YJ, Lagana A, Middleton J, Secchiero P, Garofalo M, et al. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci USA. 2015;112(28):8650–5.

  12. Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene. 2014;33(31):4069–76.

    Article  CAS  PubMed  Google Scholar 

  13. Zhang JG, Shi Y, Hong DF, Song M, Huang D, Wang CY, et al. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway. Sci Rep. 2015;5:8087.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52(1):60–70.

    Article  CAS  PubMed  Google Scholar 

  15. Sidhu K, Kapoor NR, Pandey V, Kumar V. The “Macro” World of microRNAs in Hepatocellular Carcinoma. Front Oncol. 2015;5:68.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 2013;19(33):5439–45.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014;7(1):86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma. 2013;60(2):135–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Liao Q, Han P, Huang Y, Wu Z, Chen Q, Li S, et al. Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: a meta-analysis. PLoS One. 2015;10(6):e0130677.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Yin J, Hou P, Wu Z, Wang T, Nie Y. Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol. 2015;36(6):4501–7.

    Article  CAS  PubMed  Google Scholar 

  21. Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumour Biol. 2015;36(10):7439–47.

    Article  CAS  PubMed  Google Scholar 

  22. Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123(2):630–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee SK, et al. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget. 2014;5(9):2792–806.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Yan H, Dong X, Zhong X, Ye J, Zhou Y, Yang X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog. 2014;53(12):960–9.

    CAS  PubMed  Google Scholar 

  25. Jiang F, Mu J, Wang X, Ye X, Si L, Ning S, et al. The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin- induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells. PLoS One. 2014;9(5):e96698.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Liu Q, Xu Y, Wei S, Gao W, Chen L, Zhou T, et al. miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150084.

  27. Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepato- cellular carcinoma and associated with prognosis. Med Oncol. 2014;31(6):984.

    Article  CAS  PubMed  Google Scholar 

  28. Huang S, Xie Y, Yang P, Chen P, Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS One. 2014;9(1):e81730.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Dang YW, Zeng J, He RQ, Rong MH, Luo DZ, Chen G. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev. 2014;15(12):4969–76.

    Article  PubMed  Google Scholar 

  30. Li L, Chen YY, Li SQ, Huang C, Qin YZ. Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer. Med Sci Monit. 2015;21:1155–61.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36(4):3035–42.

    Article  CAS  PubMed  Google Scholar 

  32. Pan L, Huang S, He R, Rong M, Dang Y, Chen G. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res. 2014;19:68.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol. 2012;29(5):3190–7.

    Article  CAS  PubMed  Google Scholar 

  34. Fleming NH, Zhong J, da Silva IP, Vega-Saenz de Miera E, Brady B, Han SW, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015;121(1):51–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The project was supported by the National Nature Science Foundation of China (No. 81472027, 81172141, 81200401), Nanjing Science and Technology Committee Project (No. 201108025), and Nanjing Medical Science and Technique Development Foundation (ZKX11025, QRX11254, QRX11255).

Author information

Author notes

    Authors and Affiliations

    1. Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China

      Feng Wang, Bangshun He, Yuqin Pan, Huiling Sun & Shukui Wang

    2. Medical College, Southeast University, Jiangsu, China

      Houqun Ying

    Authors
    1. Feng Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Houqun Ying
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Bangshun He
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Yuqin Pan
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Huiling Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Shukui Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Shukui Wang.

    Ethics declarations

    Conflicts of interest

    None.

    Additional information

    Feng Wang and Houqun Ying contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, F., Ying, H., He, B. et al. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma. Tumor Biol. 37, 4945–4953 (2016). https://doi.org/10.1007/s13277-015-4340-z

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-4340-z

    Keywords

    Search

    Navigation